Nephro Care India Ltd
Diversified Consumer Services | Small Cap
Nephro Care India Ltd, a key player in the Healthcare Services, showcases a mixed financial landscape. The company demonstrates strong profitability, driven by solid returns on capital, equity, and assets, coupled with healthy margins. Its growth trajectory is also impressive, marked by significant revenue and operating profit increases. However, certain areas raise concerns. Liquidity appears weak, and while solvency has improved recently, historical debt levels were high. Efficiency in utilizing assets is also a challenge. The company's earnings per share have declined. While interest coverage is strong, the absence of dividend coverage is noticeable. Overall, Nephro Care exhibits promising profitability and growth, but needs to address its liquidity and efficiency to ensure long-term financial stability.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio4.00
- Profitability Ratio10.00
- Efficiency Ratio4.67
- Coverage Ratio6.80
- Solvency Ratio8.80
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBearish
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayBearish
- 1 WeekNeutral
- 1 MonthNeutral
Nephro Care India Ltd, a key player in the Healthcare Services, showcases a mixed financial landscape. The company demonstrates strong profitability, driven by solid returns on capital, equity, and assets, coupled with healthy margins. Its growth trajectory is also impressive, marked by significant revenue and operating profit increases. However, certain areas raise concerns. Liquidity appears weak, and while solvency has improved recently, historical debt levels were high. Efficiency in utilizing assets is also a challenge. The company's earnings per share have declined. While interest coverage is strong, the absence of dividend coverage is noticeable. Overall, Nephro Care exhibits promising profitability and growth, but needs to address its liquidity and efficiency to ensure long-term financial stability.
Overall Valuation Score
P/E RATIO (TTM)
33.82
Industry Median
47.85
Small Cap Median
45.35
P/E RATIO
33.82
P/B RATIO
2.00
Industry Median
4.57
Small Cap Median
3.90
P/S RATIO
1.36
Industry Median
3.59
Small Cap Median
2.21
Others
PEG RATIO
0.00
EV/EBITDA RATIO
11.58
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹69 as on Jun 18, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company exhibits strong growth in revenue and operating profit, indicating successful expansion and improved operational performance. However, the decline in earnings per share and net income growth rate raises concerns about profitability. The company is growing in terms of revenue, operating profit and asset but Earnings per share is declining which is not good.
| Growth Ratios | Mar 2026 |
|---|---|
| Revenue Growth Rate | |
| Operating Profit Growth Rate | |
| Earnings Per Share (EPS) Growth | |
| Asset Growth Rate | |
| Net Income Growth Rate |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed outlook. While capital expenditures are well-managed, the adjusted earnings per share, cash earnings per share, and book value per share are low. There are no dividend payouts. Improving earnings per share and enhancing book value are essential for creating shareholder wealth.
| Financial Ratios | Mar 2026 |
|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 2.04 |
| Cash Earnings Per Share (Cash EPS) | 5.12 |
| Book Value Per Share | 34.46 |
| Dividend Per Share (DPS) | 0 |
| Capital Expenditures (CapEx) | 7.7 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are strong, indicating efficient operations and effective cost management. The company demonstrates high Gross Profit Margin, Return on Capital Employed (ROCE), Return on Equity (ROE), Return on Assets (ROA), Operating Margin and Net Margin. This reflects the company's ability to generate substantial profits from its revenue and investments.
| Profitability Ratios | Mar 2026 |
|---|---|
| Gross Profit Margin | 3.66 |
| Return on Capital Employed (ROCE) | 8.44 |
| Return on Equity (ROE) | 5.93 |
| Return on Assets (ROA) | 11.44 |
| Operating Margin | 9.38 |
| Net Margin | 3.8 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. While Days Sales in Inventory Ratio and Receivable Days are good, Fixed Asset Turnover Ratio, Inventory Turnover Ratio, Receivables Turnover Ratio, and Capital Turnover Ratio are low. This suggests effective management of inventory and receivables but poor utilization of assets. Improving asset turnover is essential for enhancing overall operational efficiency and maximizing returns.
| Efficiency Ratios | Mar 2026 |
|---|---|
| Fixed Asset Turnover Ratio | 2.6 |
| Inventory Turnover Ratio | 37.32 |
| Receivables Turnover Ratio | 14.69 |
| Days Sales in Inventory Ratio | 9.78 |
| Receivable Days | 24.85 |
| Capital Turnover Ratio | 1.56 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios present a mixed outlook. While the interest coverage ratio is strong, the equity dividend coverage ratio is absent. This indicates a strong ability to meet interest obligations, but a lack of dividend payouts to equity shareholders. Balancing interest coverage with equity dividend coverage would enhance shareholder value and attractiveness to investors.
| Coverage Ratios | Mar 2026 |
|---|---|
| Interest Coverage Ratio | 30 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position displays a positive shift, indicating a reduction in reliance on debt and an increase in equity. The debt ratio and debt-to-equity ratio have decreased, suggesting a more sustainable capital structure. The increasing equity ratio reflects a stronger financial foundation. The decreasing debt-to-asset ratio further supports this improved solvency. This trend enhances investor confidence and provides greater financial flexibility for future growth initiatives. The company has reduced its debt and has relied more on its assets.
| Solvency Ratios | Mar 2026 |
|---|---|
| Debt Ratio | 0 |
| Debt to Equity Ratio | 0 |
| Equity Ratio | 1 |
| Debt To Asset Ratio | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position appears weak, suggesting potential difficulties in meeting its short-term obligations. The company's current, quick, and cash ratios are low, indicating a limited ability to convert assets into cash quickly. The lack of operating cash flow further exacerbates these concerns. While this might be due to specific industry dynamics or aggressive growth strategies, it warrants careful monitoring to avoid any liquidity crisis. On a positive note, the healthcare industry can sometimes rely on predictable revenue streams, which could partially offset these low ratios.
| Liquidity Ratios | Mar 2026 |
|---|---|
| Current Ratio | 1.66 |
| Quick Ratio | 1.52 |
| Cash Ratio | 0.41 |
| Operating Cash Flow Ratio | 0.14 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Vaidya Sane Ayurved Laboratories Ltd | 7.72 | 20.63 | Undervalued | 15.00 | 4.69 | 9.00 |
| 2 | Maitreya Medicare Ltd | 7.34 | -40.14 | Neutral | -0.46 | -1.96 | -2.47 |
| 3 | Lotus Eye Hospital & Institute Ltd | 6.07 | 328.53 | Overvalued | 3.38 | 0.04 | 0.08 |
| 4 | Nephro Care India Ltd | 5.69 | 33.82 | Neutral | 8.32 | 2.04 | 3.37 |
Nephro Care India Ltd exhibits a mixed management performance. Strong growth in sales and profit, coupled with high ROCE and ROE, are positives. However, a decline in OPM and significant increase in liabilities raise concerns. Stable promoter holding is a positive, but fluctuating institutional holdings indicate some uncertainty. Overall, management shows both strengths and areas needing attention.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (TTM) | 69% | Demonstrates strong revenue expansion |
| ROCE | 62.97% | Indicates efficient capital utilization | |
| CONS | OPM (Mar 2025) | 9.99% | Shows a concerning decline in operating margin |
| Total Liabilities (Mar 2025) | 68.28 | Signals potential financial strain |
Financial Performance & Growth
Nephro Care India Ltd. has demonstrated strong sales growth, but profit growth has been volatile. The company's revenue has increased significantly over the years.The Compounded Sales Growth is 138% over the past 3 years and 69% TTM. However, while sales growth has been strong, profit growth has shown some volatility.The Compounded Profit Growth is 123% over the past 3 years, but it shows a decline of -16% TTM. The operating profit margin (OPM) has seen fluctuations, with a recent decline in Mar 2025 to 9.99%, compared to 19.25% in Mar 2024 and 17.18% in Sep 2024. Net profit has also fluctuated, with a recent figure of 1.45 in Mar 2025, compared to 0.76 in Mar 2024 and 2.19 in Sep 2024.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Sales | 17.09 | 27.23 | 46.03 |
| Sales Growth % | 400% | 59% | 69% |
| Operating Profit | 3.43 | 6.47 | 5.87 |
| OPM % | 20.07% | 23.76% | 12.75% |
Capital Efficiency & Returns
Nephro Care India Ltd demonstrates excellent capital efficiency and returns. The Return on Capital Employed (ROCE) is reported at an impressive 62.97%, and the Return on Equity (ROE) stands at a robust 51.30%. The Cash Conversion Cycle is efficient, showing negative values, indicating effective management of working capital. However, there is a notable decrease in ROCE from 60.41% in Mar 2024 to 14.42% in Mar 2025.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| ROCE % | 65.84% | 60.41% | 14.42% |
Financial Health & Prudence
Nephro Care India Ltd shows some concerning trends in its financial health. While the company has eliminated borrowings, as reflected in zero long-term and short-term borrowings in Mar 2024 and Mar 2025, total liabilities have substantially increased. Total Liabilities have increased significantly from 8.26 in Mar 2023 to 20.96 in Mar 2024 and further to 68.28 in Mar 2025. Interest coverage is not applicable due to the absence of borrowings. The company has not been paying dividends, with a Dividend Payout % of 0.00% across the years.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Borrowings | 2.48 | 0.00 | 0.00 |
| Total Liabilities | 8.26 | 20.96 | 68.28 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
Shareholding & Ownership Structure
Nephro Care India Ltd's shareholding pattern reveals moderate confidence in the company. Promoter holding is relatively stable at 61.44% in Mar 2025. However, there is fluctuation in institutional holdings.FII holdings have decreased from 3.92% in Sep 2024 to 3.50% in Mar 2025, and DII holdings have also decreased from 4.82% in Sep 2024 to 2.24% in Mar 2025. Public holding has increased from 29.87% in Sep 2024 to 32.82% in Mar 2025.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|
| Promoters | 61.38% | 61.38% | 61.44% |
| FIIs | 3.92% | 4.06% | 3.50% |
| DIIs | 4.82% | 3.41% | 2.24% |
| Public | 29.87% | 31.14% | 32.82% |
Nephro Care India Ltd presents a moderate risk profile due to strengths in sales growth and profitability, alongside efficient working capital management and high returns on capital. However, the significant increase in total liabilities, along with fluctuations in operating profit margin and institutional holdings, raise concerns.
Accounting quality red flags
The data shows fluctuating tax percentages, such as 69.35% in Mar 2024 and 27.33% in Sep 2024, which could indicate variations in accounting practices or one-time adjustments that may warrant further investigation. Tax % has been 20.22% in Mar 2025.
Segment performance volatility
Operating Profit Margin (OPM) has fluctuated from 19.25% in Mar 2024 to 17.18% in Sep 2024 and then dropped to 9.99% in Mar 2025. This indicates some volatility in the company's operational efficiency.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1068.41Bearish
- SMA 2068.47Bearish
- SMA 5068.88Bearish
- EMA 1068.22Bearish
- EMA 2068.45Bearish
- EMA 5069.32Bearish
- DEMA 1067.93Bullish
- DEMA 2068.05Bearish
- DEMA 5067.61Bullish
- TEMA 1067.76Bullish
- TEMA 2068.13Bearish
- TEMA 5067.94Bullish
- MACD-0.31Bearish
- ADX17.61Weak Trend
- IndicatorValueSignal
- RSI43.37Neutral
- CCI-77.14Neutral
- ROC 9-1.23Bearish
- ROC 14-1.23Bearish
- ROC 25-1.45Bearish
- Stoch K15.00Oversold
- Stoch D15.67Oversold
- IndicatorValueSignal
- BB Upper69.66Neutral
- BB Middle68.47Neutral
- BB Lower67.28Neutral
- ATR0.68Low Volatility
- IndicatorValueSignal
- MFI35.55Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1068.53Bearish
- SMA 2068.61Bearish
- SMA 5070.61Bearish
- EMA 1068.41Bearish
- EMA 2068.84Bearish
- EMA 5070.72Bearish
- DEMA 1068.10Bearish
- DEMA 2067.85Bullish
- DEMA 5067.49Bullish
- TEMA 1068.12Bearish
- TEMA 2068.11Bearish
- TEMA 5067.19Bullish
- MACD-0.69Bullish
- ADX31.33Strong Trend
- IndicatorValueSignal
- RSI40.11Neutral
- CCI-101.73Oversold
- ROC 9N/ABearish
- ROC 14-1.31Bearish
- ROC 25-1.45Bearish
- Stoch K18.00Oversold
- Stoch D25.33Neutral
- IndicatorValueSignal
- BB Upper69.68Neutral
- BB Middle68.60Neutral
- BB Lower67.53Neutral
- ATR1.13Low Volatility
- IndicatorValueSignal
- MFI35.45Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1068.59Bearish
- SMA 2070.27Bearish
- SMA 5074.53Bearish
- EMA 1068.83Bearish
- EMA 2070.08Bearish
- EMA 5073.19Bearish
- DEMA 1067.85Bullish
- DEMA 2067.55Bullish
- DEMA 5070.10Bearish
- TEMA 1068.06Bearish
- TEMA 2067.64Bullish
- TEMA 50N/AN/A
- MACD-1.81Bullish
- ADX24.77Weak Trend
- IndicatorValueSignal
- RSI37.44Neutral
- CCI-66.42Neutral
- ROC 9-1.73Bearish
- ROC 14-4.29Bearish
- ROC 250.52Bullish
- Stoch K25.22Neutral
- Stoch D25.25Neutral
- IndicatorValueSignal
- BB Upper75.40Neutral
- BB Middle70.28Neutral
- BB Lower65.15Neutral
- ATR2.16Low Volatility
- IndicatorValueSignal
- MFI54.25Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1070.65Bearish
- SMA 2073.66Bearish
- SMA 5078.93Bearish
- SMA 10079.54Bearish
- SMA 200107.82Bearish
- EMA 1070.41Bearish
- EMA 2072.83Bearish
- EMA 5076.52Bearish
- EMA 10084.16Bearish
- EMA 200102.81Bearish
- DEMA 1068.00Bullish
- DEMA 2069.10Bearish
- DEMA 5070.85Bearish
- DEMA 10066.86Bullish
- DEMA 20066.66Bullish
- TEMA 1068.12Bullish
- TEMA 2067.19Bullish
- TEMA 5073.00Bearish
- TEMA 10068.59Bullish
- TEMA 200N/AN/A
- MACD-2.89Bearish
- ADX24.39Weak Trend
- IndicatorValueSignal
- RSI38.15Neutral
- CCI-68.77Neutral
- ROC 14-9.51Bearish
- ROC 25-13.26Bearish
- Stoch K24.97Neutral
- Stoch D21.88Neutral
- IndicatorValueSignal
- BB Upper83.42Neutral
- BB Middle73.66Neutral
- BB Lower63.89Neutral
- ATR4.17High Volatility
- IndicatorValueSignal
- MFI48.38Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 2078.88Bearish
- SMA 50112.20Bearish
- EMA 2083.85Bearish
- EMA 50110.30Bearish
- DEMA 2068.76Bullish
- DEMA 5067.69Bullish
- TEMA 2070.98Bearish
- TEMA 50N/AN/A
- MACD-10.52Bullish
- ADX17.59Weak Trend
- IndicatorValueSignal
- RSI39.60Neutral
- CCI-100.79Oversold
- ROC 14-4.20Bearish
- ROC 25-41.27Bearish
- Stoch K57.78Neutral
- Stoch D58.67Neutral
- IndicatorValueSignal
- BB Upper105.90Neutral
- BB Middle78.88Neutral
- BB Lower51.87Neutral
- ATR12.58Low Volatility
- IndicatorValueSignal
- MFI29.53Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
No results for this timeframe
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 682.55Bearish
- SMA 12110.69Bearish
- SMA 24N/AN/A
- EMA 685.82Bearish
- EMA 12111.17Bearish
- EMA 24N/AN/A
- DEMA 667.09Bullish
- DEMA 1265.47Bullish
- DEMA 24N/AN/A
- TEMA 668.67Bullish
- TEMA 12N/AN/A
- TEMA 24N/AN/A
- MACDN/AN/A
- ADXN/AN/A
- IndicatorValueSignal
- RSIN/AN/A
- CCIN/AN/A
- ROC 25N/AN/A
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper231.79Neutral
- BB Middle135.62Neutral
- BB Lower39.45Neutral
- ATR41.62Low Volatility
- IndicatorValueSignal
- MFI56.29Neutral